United States Insulin Syringes Market To Witness Remunerative Growth Over 2021-2027

January 12, 2022


According to the research report titled ‘United States Insulin Syringes Market and Forecast 2021 – 2027’, available with MarketStudyReport, United States insulin syringes market is projected to surpass USD 1 billion over the forecast timespan 2021-2027.
 

Surging number of diabetic patients due to expanding ageing population, increased risk of diabetes due to adoption of unhealthy lifestyles, and favorable government regulations are the primary factors propelling the United States insulin syringes market growth.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4259144/
 

Emerging economies are expected to provide significant future growth prospects for industry participants. On the contrary, increasing usage of insulin pens and high costs of improved insulin syringes might hamper the product demand in the forthcoming years.
 

For those unfamiliar, insulin controls the body's fat and glucose metabolism. It is a peptide hormone that is released in the pancreas by beta cells and aids in regulating glucose metabolism. An insulin syringe helps diabetic individuals get their insulin in the right doses. They are made up of three parts: a needle, a barrel, and a plunger, and come in a variety of sizes.
 

Apart from the aforementioned, the market research also includes historical data from 2019-2020, as well as an illustrative projection to 2027, which includes major facets such as market value, volume, and pricing analysis for insulin syringes.
 

Considering the competitive landscape, Advocate Meters (Pharma Supply Inc.), Becton, Dickinson, and Company (BD), Arkray, Inc., UltiMed Inc., Allison Medical Inc., Cardinal Health Inc., Abbott Diabetes Care, Smiths Medical Inc., Eli Lilly and Co., Trividia Health Inc., MHC Medical Products LLC, Home Aide Diagnostics Inc., Retractable Technologies Inc., Prodigy Diabetes Care LLC, and AdvaCare Pharma USA LLC, are the major contributors to the United States insulin syringes industry. Their financials and policies are discussed to aid other businesses to make informed decisions throughout the assessment period.

Chat with us